Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus

Hiroyuki Konya,1 Tomoyuki Katsuno,2 Taku Tsunoda,1 Yuzo Yano,1 Mai Kamitani,1 Masayuki Miuchi,2 Tomoya Hamaguchi,3 Jun-Ichiro Miyagawa,2 Mitsuyoshi Namba2 1Department of Internal Medicine, Ashiya Municipal Hospital, Ashiya, Hyogo, Japan; 2Division of Diabetes, Endocrinology and Metabolism, Departmen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Konya H, Katsuno T, Tsunoda T, Yano Y, Kamitani M, Miuchi M, Hamaguchi T, Miyagawa JI, Namba M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/86344b51a0584bed8688f92f94955ea7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:86344b51a0584bed8688f92f94955ea7
record_format	dspace
spelling	oai:doaj.org-article:86344b51a0584bed8688f92f94955ea72021-12-02T05:53:27ZEffects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus1178-7007https://doaj.org/article/86344b51a0584bed8688f92f94955ea72013-09-01T00:00:00Zhttp://www.dovepress.com/effects-of-combination-therapy-with-mitiglinide-and-voglibose-on-postp-a14228https://doaj.org/toc/1178-7007Hiroyuki Konya,1 Tomoyuki Katsuno,2 Taku Tsunoda,1 Yuzo Yano,1 Mai Kamitani,1 Masayuki Miuchi,2 Tomoya Hamaguchi,3 Jun-Ichiro Miyagawa,2 Mitsuyoshi Namba2 1Department of Internal Medicine, Ashiya Municipal Hospital, Ashiya, Hyogo, Japan; 2Division of Diabetes, Endocrinology and Metabolism, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; 3Division of Innovative Diabetes Treatment, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan Abstract: Patients with diabetes mellitus are at increased risk from cardiovascular-related morbidity and mortality as compared with healthy individuals. An association between the postprandial metabolic state and atherogenesis has been observed in patients with diabetes mellitus. In the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM), treatment with an α-glucosidase inhibitor (α-GI) in patients with impaired glucose tolerance not only reduced the rate of conversion from impaired glucose tolerance to type 2 diabetes mellitus (T2DM), but was also associated with a reduction in the risk of cardiovascular events. These results suggested the importance of treating postprandial hyperglycemia in the early stages of T2DM. Glinides are rapid and short-acting insulin secretagogues that bind to the sulfonylurea receptors on pancreatic β-cells to facilitate rapid insulin secretion, restore postprandial early insulin secretion, and reduce the postprandial glucose spike. Moreover, α-GIs reduce postprandial hyperglycemia and insulin secretion by delaying the digestion of carbohydrates and polysaccharides in the small intestine. Then, both glinides and α-GI have beneficial effects for treating patients with T2DM and impaired glucose tolerance. Considering the ameliorating effects of these drugs on postprandial metabolic disorders, combinations of glinides and α-GI might constitute a promising therapeutic strategy for managing patients with T2DM, and also appear to be suitable for Japanese people, who consume more carbohydrates, such as polished rice, than Caucasians. It has recently been reported that combined use of mitiglinide and voglibose reduces postprandial insulin secretion and blunts diurnal glycemic changes in T2DM patients. This therapy can thus be regarded as being suitable for achieving strict postprandial glycemic control. In this report, we outline the effects of this combination therapy on postprandial plasma glucose and assess its safety. Keywords: mitiglinide, voglibose, combination therapy, type 2 diabetes mellitus, postprandial hyperglycemiaKonya HKatsuno TTsunoda TYano YKamitani MMiuchi MHamaguchi TMiyagawa JINamba MDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2013, Iss default, Pp 317-325 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Konya H Katsuno T Tsunoda T Yano Y Kamitani M Miuchi M Hamaguchi T Miyagawa JI Namba M Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus
description	Hiroyuki Konya,1 Tomoyuki Katsuno,2 Taku Tsunoda,1 Yuzo Yano,1 Mai Kamitani,1 Masayuki Miuchi,2 Tomoya Hamaguchi,3 Jun-Ichiro Miyagawa,2 Mitsuyoshi Namba2 1Department of Internal Medicine, Ashiya Municipal Hospital, Ashiya, Hyogo, Japan; 2Division of Diabetes, Endocrinology and Metabolism, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan; 3Division of Innovative Diabetes Treatment, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan Abstract: Patients with diabetes mellitus are at increased risk from cardiovascular-related morbidity and mortality as compared with healthy individuals. An association between the postprandial metabolic state and atherogenesis has been observed in patients with diabetes mellitus. In the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM), treatment with an α-glucosidase inhibitor (α-GI) in patients with impaired glucose tolerance not only reduced the rate of conversion from impaired glucose tolerance to type 2 diabetes mellitus (T2DM), but was also associated with a reduction in the risk of cardiovascular events. These results suggested the importance of treating postprandial hyperglycemia in the early stages of T2DM. Glinides are rapid and short-acting insulin secretagogues that bind to the sulfonylurea receptors on pancreatic β-cells to facilitate rapid insulin secretion, restore postprandial early insulin secretion, and reduce the postprandial glucose spike. Moreover, α-GIs reduce postprandial hyperglycemia and insulin secretion by delaying the digestion of carbohydrates and polysaccharides in the small intestine. Then, both glinides and α-GI have beneficial effects for treating patients with T2DM and impaired glucose tolerance. Considering the ameliorating effects of these drugs on postprandial metabolic disorders, combinations of glinides and α-GI might constitute a promising therapeutic strategy for managing patients with T2DM, and also appear to be suitable for Japanese people, who consume more carbohydrates, such as polished rice, than Caucasians. It has recently been reported that combined use of mitiglinide and voglibose reduces postprandial insulin secretion and blunts diurnal glycemic changes in T2DM patients. This therapy can thus be regarded as being suitable for achieving strict postprandial glycemic control. In this report, we outline the effects of this combination therapy on postprandial plasma glucose and assess its safety. Keywords: mitiglinide, voglibose, combination therapy, type 2 diabetes mellitus, postprandial hyperglycemia
format	article
author	Konya H Katsuno T Tsunoda T Yano Y Kamitani M Miuchi M Hamaguchi T Miyagawa JI Namba M
author_facet	Konya H Katsuno T Tsunoda T Yano Y Kamitani M Miuchi M Hamaguchi T Miyagawa JI Namba M
author_sort	Konya H
title	Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus
title_short	Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus
title_full	Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus
title_fullStr	Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus
title_full_unstemmed	Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus
title_sort	effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/86344b51a0584bed8688f92f94955ea7
work_keys_str_mv	AT konyah effectsofcombinationtherapywithmitiglinideandvogliboseonpostprandialplasmaglucoseinpatientswithtype2diabetesmellitus AT katsunot effectsofcombinationtherapywithmitiglinideandvogliboseonpostprandialplasmaglucoseinpatientswithtype2diabetesmellitus AT tsunodat effectsofcombinationtherapywithmitiglinideandvogliboseonpostprandialplasmaglucoseinpatientswithtype2diabetesmellitus AT yanoy effectsofcombinationtherapywithmitiglinideandvogliboseonpostprandialplasmaglucoseinpatientswithtype2diabetesmellitus AT kamitanim effectsofcombinationtherapywithmitiglinideandvogliboseonpostprandialplasmaglucoseinpatientswithtype2diabetesmellitus AT miuchim effectsofcombinationtherapywithmitiglinideandvogliboseonpostprandialplasmaglucoseinpatientswithtype2diabetesmellitus AT hamaguchit effectsofcombinationtherapywithmitiglinideandvogliboseonpostprandialplasmaglucoseinpatientswithtype2diabetesmellitus AT miyagawaji effectsofcombinationtherapywithmitiglinideandvogliboseonpostprandialplasmaglucoseinpatientswithtype2diabetesmellitus AT nambam effectsofcombinationtherapywithmitiglinideandvogliboseonpostprandialplasmaglucoseinpatientswithtype2diabetesmellitus
_version_	1718400181515321344

Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus

Ejemplares similares